The Alzheimer’s-afflicted brain is like a garden that has become choked with weeds (amyloid plaques), overrun by destructive pests (abnormal tau), and worn down by severe weather (inflammation). Fortunately, as this month’s cover story explains, each of these threats is being targeted by antibody-based drugs. Indeed, drug developers are looking into combination therapies. And to ensure that therapies are deployed earlier, and to greater effect, investigators are working on blood-based biomarkers. In this issue of GEN, the idea of taming out-of-control processes, and thereby restoring health, isn’t limited to antibody-based Alzheimer’s drugs. It is reflected in feature articles on phage therapies, RNA-based vaccines and drugs, and RNA editing platforms. In addition, this issue of GEN invites readers to look at 3D cell cultures as gardens that can represent the complex ecologies that exist in human tissues. Specifically, organoids are presented as suitable testing grounds for drug developers. Finally, we report on sample prep kits that facilitate the cultivation of lush DNA libraries.